TissueTech to Collaborate with Johns Hopkins University-based Investigators

DMCA.com Protection Status
Keywords: 
Blog Category: 

By Industry News

Miami, FL – August 17, 2020 – Amniox Medical, Inc. (Amniox), a TissueTech, Inc. company involved in the research of the clinical application of human birth tissue-based products, announced today that Yun Guan, MD, PhD, professor of anesthesiology and critical care medicine, and professor of neurological surgery at the Johns Hopkins University School of Medicine, has been awarded a 5-year R01 grant from the National Institutes of Health (NIH) for a study titled “Birth Tissue Products for Non-opioid Treatment of Post-surgical Pain.” Dr. Guan and his team will study the efficacy and molecular mechanism, thereby human birth tissue promotes wound healing and suppresses pain after surgical procedures. TissueTech will serve as a sub-contractor on the project.

Earlier studies conducted by Dr. Guan in collaboration with TissueTech suggest that TissueTech human birth tissue allografts may promote wound healing while reducing pain sensitization. “The long-term goal of this research is to demonstrate the efficacy, receptor mechanisms, and safety of human birth tissue as well as the major matrix component, i.e., HC-HA/PTX3 in the birth tissue, in promoting wound healing and inhibiting post-surgical pain,” said Dr. Guan. “I am especially proud to collaborate with Dr. Scheffer Tseng and his team at TissueTech on this initiative. In the context of our nation’s current opioid epidemic, health care providers face challenges of simultaneously optimizing postoperative pain management and limiting opioid use after surgery. Modifiable risk factors and novel non-opioid treatment options can reduce the risk of chronic opioid use after surgery. This is one reason that this study is so important.”

“Our collaborative efforts using various pre-clinical models also disclose that HC-HA/PTX3, a key bioactive compomnet in the birth tissue, is responsible for promoting regenerative healing by curtailing surgically-induced inflammation and nociceptive pain at the same time in this pre-clinical study,” said Dr. Tseng, the Chief Technology Officer of TissueTech.

The Research Project Grant (R01) is the original and historically oldest grant mechanism used by the NIH. It provides support for health-related research and development based on the mission of the NIH, which is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthens life, and reduce illness and disability.

About Amniox Medical, Inc.
AMNIOX® Medical, Inc. is the first provider of a cryopreserved matrix comprised of human umbilical cord that can be stored in a refrigerator for up to two years and is ready to use without thawing, transplanting the benefits of regenerative healing for non-healing and chronic wounds.

About TissueTech, Inc.
TissueTech, Inc., the parent company of Amniox Medical, Inc. and Bio-Tissue, Inc., is a scientific and market leader in the field of regenerative medicine.

The views and opinions expressed in this blog are solely those of the author, and do not represent the views of WoundSource, Kestrel Health Information, Inc., its affiliates, or subsidiary companies.

Related company: 

Recommended for You

  • WoundSource 2019
    August 22nd, 2019

    By Miranda J. Henry, Editorial Director of WoundSource

    This updated edition of WoundSource provides a glimpse of the continuing evolution of the field of wound care. There are several additions this year that reflect the innovation and ingenuity we are seeing in wound...

  • August 5th, 2020

    By Heidi Cross, MSN, RN, FNP-BC, CWON

    Pressure injury risk and development are multifactorial, individualized processes. Each patient presents with a unique set of circumstances and needs. In looking at charts for attorneys to determine whether standards of care related to...

  • July 30th, 2020

    By Cheryl Carver, LPN, WCC, CWCA, DAPWCA, FACCWS

    I am into my 20th year working as a wound care specialist. I must admit, I never thought much about wound management in the prison population until my son's wound care experiences during his incarcerations. I am quite transparent...

Important Notice: The contents of the website such as text, graphics, images, and other materials contained on the website ("Content") are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. The content is not intended to substitute manufacturer instructions. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or product usage. Refer to the Legal Notice for express terms of use.